Search the Newsreel

Biogen (BIIB) Stock Revenue Holds While Margins and EPS Retreat

Biogen's Q2 2026 earnings showed steady revenue but a significant decline in net income and EPS due to margin squeeze and acquisition costs. While growth products like SYFOVRE and EMPAVELI are performing well, the company's profitability is being impacted by R&D and deal charges. …

Why Biogen (BIIIB) Is Up 5.8% After Q2 Revenue Beat And Raised 2026 Guidance - And What's Next

Biogen (BIIB) saw its stock rise by 5.8% after reporting strong Q2 2026 results with revenue beating expectations and raised 2026 guidance. This performance was driven by its expanding growth portfolio and the Apellis acquisition, which are offsetting declining sales in legacy multiple sclerosis …

BIIB Maintains Rating by Morgan Stanley -- Price Target Raised to $231

Morgan Stanley has reiterated its "Equal-Weight" rating for Biogen (BIIB) and increased its price target from $222.00 to $231.00. Despite this positive adjustment, GuruFocus's GF Value™ indicates that Biogen is currently 7.2% overvalued. The company's GF Score™ of 68/100 points to strong profitability and …

Biogen accelerates lupus and rejection trials to H1 2027 as lecanemab subcutaneous reshapes Alzheimer's access

Biogen's Q2 2026 earnings call highlighted five upcoming registrational readouts for lupus, antibody-mediated rejection, and Dravet syndrome, with a significant announcement being the FDA approval of a subcutaneous lecanemab formulation for Alzheimer's. The company accelerated trials for lupus and antibody-mediated rejection to H1 2027, …

Canaccord raises Biogen stock price target to $248 on strong quarter

Canaccord Genuity increased its price target for Biogen Inc. (NASDAQ:BIIB) to $248 from $245, maintaining a Buy rating after the company's strong second-quarter results. Biogen surpassed revenue and EPS estimates with $2.74 billion and $3.60, respectively, driven by solid performance in its multiple sclerosis …

Guggenheim reiterates Biogen stock rating on stabilized revenue

Guggenheim reiterated a Buy rating and $280 price target on Biogen Inc. following strong quarterly results that surpassed Wall Street expectations, with revenues stabilizing after genericization headwinds. The firm believes Biogen is set for sustainable growth due to its scaled growth portfolio, the Apellis …

Guggenheim reitera su calificación de Biogen por la estabilización de los ingresos

Biogen’s 68% surge validates InvestingPro Fair Value analysis By Investing.com

InvestingPro's Fair Value models identified Biogen (NASDAQ:BIIB) as undervalued nearly a year ago, predicting a significant upside. The stock subsequently surged by over 67%, reaching and exceeding the initial Fair Value target, validating InvestingPro's analytical approach. This success highlights how comprehensive valuation analysis can …

UBS Adjusts Price Target on Biogen to $240 From $225, Maintains Buy Rating

UBS has increased its price target for Biogen (BIIB) to $240, up from the previous $225, while reiterating a "Buy" rating for the pharmaceutical company. This adjustment comes amidst other analyst revisions, including RBC trimming its price target to $240 and JPMorgan lifting its …

Warum Biogen (BIIB) nach über den Erwartungen liegenden Umsätzen im zweiten Quartal und einer Anhebung der Prognose für 2026 um 5,8 % zulegt – und wie es weitergeht

Por qué Biogen (BIIB) ha subido un 5,8 % tras superar las previsiones de ingresos del segundo trimestre y revisar al alza sus previsiones para 2026, y qué se espera a partir de ahora

Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?

Biogen (BIIB) reported Q2 2026 revenue growth to US$2.74 billion, up from US$2.65 billion year-over-year, but net income sharply compressed to US$97.5 million from US$4.33 million the previous year. This earnings compression, despite revenue increases, is raising questions about future profitability, especially as the …

Biogen lifts revenue outlook as Apellis deal delivers early wins

Biogen has raised its full-year revenue forecast for 2026, driven by stronger-than-expected sales of its multiple sclerosis drug, Tysabri, and its newly acquired eye drug, Izervay, from the Apellis deal. The company anticipates a substantial contribution from Izervay, projecting its sales to reach $80 …

Why Biogen Stock Topped the Market Today

One of these enterprises was Biogen (NASDAQ: BIIB), which did quite well in its second quarter. As a reward, investors snapped up the stock, sending it to a nearly 2% gain on the day. This beat the S&P 500 index's 0.2% rise. A biotech …

Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and ...

This article first appeared on GuruFocus. Total Revenue: $2.7 billion, up 3% year over year. Core Pharmaceutical Revenue: $1.8 billion, up 4% year over year and 12% quarter over quarter. Growth Portfolio Revenue: Over $1 billion, up 24% year over year and 25% quarter …

Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and Promising Pipeline Developments

Biogen Inc. reported a 3% year-over-year revenue increase in Q2 2026, reaching $2.7 billion, driven by strong performance in its core pharmaceuticals and growth portfolio, which includes SPINRAZA, LEQEMBI, and SKYCLARYS. Despite market challenges and increased operating expenses from acquisitions and pipeline investments, the …

Biogen Inc (BIIB) approaches results with a one-month pullback in focus

The neurology-focused biotech reports July 29, with expectations modest and recent price action softer despite a still-positive three-month tape.

Is Biogen (BIIB) Undervalued Following Its Q2 2026 Earnings?

Biogen (BIIB) has reported its Q2 2026 earnings, leading analysts to assess its valuation. Despite recent share price gains, the company is seen as 9.7% undervalued, with a fair value of $227.59 compared to its current price of $205.61, largely due to the potential …

Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push

This article provides an earnings roundup for Biogen, AstraZeneca, and GSK. Biogen demonstrated "resiliency" with better-than-expected revenue and product sales, though full-year guidance was lowered due to acquisition costs. AstraZeneca is pitching an ambitious growth plan to hit $80 billion in sales by 2030, …

Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised

Biogen (BIIB) reported strong Q2 2026 results, beating earnings and revenue estimates due to robust sales from new drugs like Skyclarys, Qalsody, and Zurzuvae, as well as contributions from recently acquired Empaveli and Syfovre. Despite a decline in legacy multiple sclerosis drug sales, the …

Biogen flips '26 guidance from expected decline to sales increase

Biogen has revised its 2026 revenue guidance from an expected mid-single-digit decline to an increase, largely due to strong performance from newer drugs and the acquisition of Apellis Pharmaceuticals. CEO Chris Viehbacher stated the company is positioned for long-term growth as these new products …

Transcript : Biogen Inc., Q2 2026 Earnings Call, Jul 29, 2026

This article provides details about Biogen Inc.'s Q2 2026 earnings call transcript and related news. It includes information on their financial results for the second quarter and six months ended June 30, 2026, highlighting a non-GAAP earnings fall despite rising revenue. The company also …

Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Biogen Inc. (BIIB) reported $2.74 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 3.4%. EPS of $3.60 for the same period compares to $5.47 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $2.5 …

Biogen Inc. presenta sus resultados financieros del segundo trimestre y del primer semestre de 2026

Biogen Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:BIIB) 2026-07-29

This article presents the Biogen Inc. Q2 2026 earnings call presentation. Key financial highlights include an EPS of $3.60, beating estimates by $1.57, and revenue of $2.74 billion, a 3.42% year-over-year increase, surpassing estimates by $275.37 million. The slide deck was published in conjunction …

Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026

Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026 Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts' consensus estimates. Is now the time to …

Biogen beats quarterly estimates as newer drugs drive growth

Biogen exceeded Wall Street's expectations for its second-quarter profit and revenue, driven by strong growth in its rare-disease medications despite a decline in sales of its older multiple sclerosis drugs. The company raised its full-year revenue forecast to a mid-single-digit percentage growth, a significant …

Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates

Biogen Inc. (BIIB) came out with quarterly earnings of $3.6 per share, beating the Zacks Consensus Estimate of $3.04 per share. This compares to earnings of $5.47 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Biogen posts Q2 beat and updates 2026 outlook (BIIB:NASDAQ)

Biogen (BIIB) reported better-than-expected Q2 2026 results, driven by strong performance in its growth portfolio, which includes newer medicines like Zurzuvae and Skyclarys. The company raised its full-year revenue outlook to mid-single-digit percentage growth, despite a minor underperformance from Leqembi and a reduced EPS …

Is Biogen Inc (BIIB) Overvalued After Q2 Earnings With EPS of $0.66 and Revenue of $2,736 Million? GF Score: 69/100

Biogen Inc (BIIB) reported Q2 2026 revenue of $2.736 billion, a 3% increase year-over-year, and a GAAP diluted EPS of $0.66. While its Growth Portfolio revenue surpassed its legacy MS portfolio, declining revenue from foundational MS products remains a challenge. GuruFocus rates BIIB with …

Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales

Investing.com -- Biogen reported second-quarter revenue and adjusted profit above analysts' estimates on Wednesday, helped by 24% growth in its Growth Portfolio and stronger revenue from recently acquired products, although sales of its Alzheimer's drug Leqembi narrowly missed expectations. Revenue rose 3% to $2.74 …

Biogen Cuts FY Adjusted View as Profit Declines

Biogen (BIIB) reported a significant decline in its second-quarter profit and subsequently lowered its full-year adjusted earnings forecast. The biopharmaceutical company attributed the reduced profit and revised outlook to deal-related charges, research and development expenses, the acquisition of Apellis, and ongoing investments in Phase …

Biogen beats top-line and bottom-line estimates; updates FY26 outlook

* Biogen press release [https://seekingalpha.com/filing/309872127] (BIIB [https://seekingalpha.com/symbol/BIIB]): Q2 Non-GAAP EPS of $3.60 beats by $1.57. * Revenue of $2.7B (+3.8% Y/Y) beats by $240M. * SPINRAZA revenue of $402 million, up 2% year-over-year. * VUMERITY second quarter revenue of $197 million, down 7% year-over-year, …

Biogen reports Q2 2026: $2.74B revenue, GAAP EPS $0.66, Non‑GAAP EPS $3.60

Biogen reported its second-quarter 2026 results, showing total revenue of $2.74 billion, a 3% increase year-over-year. The company posted GAAP diluted EPS of $0.66 and non-GAAP diluted EPS of $3.60, with its Growth Portfolio contributing $1.06 billion, up 24% year-over-year. Biogen also updated its …

Biogen beats quarterly estimates as newer drugs fuel growth

July 29 (Reuters) - Biogen reported second-quarter profit and revenue that topped Wall Street estimates on Wednesday, driven by strong demand ‌for its rare-disease medicines, while sales of its legacy multiple ‌sclerosis drugs stayed under pressure. Investors are closely watching whether recent deals and …

Biogen Q2 revenue rises 3% to $2.7B

Biogen announced a 3% increase in its second-quarter revenue, reaching $2.7 billion. This growth indicates a positive financial performance for the company during the quarter.